Découvrez Les acteurs de l’éco sur LN24
Découvrez Les acteurs de l’éco sur LN24 Notre CEO, Ludivine Coulon a été invité par Bruno Wattenbergh pour s’exprimer sur les enjeux stratégiques de la propriété intellectuelle. https://www.ln24.be/2020-10-09/les-acteurs-de-leco-comment-se-portent-leconomie-et-les-entreprises-belgeshttps://lnkd.in/gWvwpqA
CALYSTA awarded by IAM TOP Patent Professionals
And hupla, a new ranking is again achieved ! CALYSTA NV is ranked in the IAM PATENT 1000 list as RECOMMENDED PATENT PROSECUTION FIRM 2020 IN BELGIUM This is how IAM – Informing
IP STARS at CALYSTA
CALYSTA NV did it again… After the wonderful recognition of our RISING STAR 20/21 Clara De Schryver and our PATENT STAR 20/21 Ludivine Coulon – Romain Lobera has now been named as NOTABLE PRACTITIONER by IP STARS ! Romain
The challenges of protecting your software
More and more innovations nowadays are implemented partly or fully in Software. Many developers believe that software innovations are not patentable. This short article gives you a short overview how
Do you like scary movies ?
Do you like scary movies (with protected IP)? The so-called Ghostface mask was created almost 3 decades ago and became iconic because of its use in the 1996 film “Scream”.
Copyright is for losers… yet it turns out to be the only IP right protecting Banksy’s artwork
As a result of a recent ruling by the EUIPO Cancellation Division, street artist Banksy has lost a two-year trademark battle with “Full Color Black”, a company selling greeting cards,
The challenges IP is facing from 3D printing
Additive manufacturing has the potential to dramatically facilitate manufacturing processes and facilitate the copying of innovative products. The following article analyses the different challenges caused by 3D printing for the
Breaking IP News – New decision concerning the extension of patent duration for new indication of known products
After the controversial topic of chloroquine, an anti-malaria remedy potentially active against Covid 19 virus, the new decision of the EUCJ concerning the extension of patent duration for new indication